Sofinnova Ventures is sticking with what works for its second life sciences-only fund, which the firm closed last week at $500 million.

The fund, the firm's ninth overall, was oversubscribed and was originally targeting $425 million. It will invest primarily in therapeutics companies and will focus on areas like specialty products and Orphan diseases. Similar to Sofinnova